Skip to content

Clinical study on the treatment outcome of IVF-ET with controlled ovarian stimulation by combined GH in elderly patients with DOR

Clinical study on the treatment outcome of IVF-ET with controlled ovarian stimulation using PPOS protocol combined with GH in elderly patients with DOR

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117658
Enrollment
Unknown
Registered
2026-01-27
Start date
2023-03-06
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Experimental group:The patients included were stratified by age into single-factor blocks and divided into three groups: 35-37 years old, 38-40 years old, and >=41 years old. Then, patients in each gr
Control group:The patients included were stratified by age into single-factor blocks and divided into three groups: 35-37 years old, 38-40 years old, and >=41 years old. Then, the patients in each gro

Sponsors

The Second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 35 years old; 2. Patients with diminished ovarian reserve (DOR): Satisfy any 2 of the following criteria to meet the diagnosis of DOR: AMH = 10 IU/L or estrogen >= 80 pg/ml (The above standards are derived from the DOR diagnostic criteria formulated in the Chinese Expert Consensus on the Clinical Diagnosis and Treatment of Diminished Ovarian Reserve); 3. Patients who undergo superovulation with the high progesterone-based ovulation induction PPOS protocol.

Exclusion criteria

Exclusion criteria: 1. Age less than 35 years old; 2. Those with contraindications for assisted reproductive technology or pregnancy restrictions; 3. Individuals with chromosomal abnormalities in either partner, except for advanced age, have obvious causes that may lead to DOR, such as history of ovarian cystectomy, history of unilateral ovary resection, or history of fallopian tube resection, etc.; 4. Individuals with uterine anatomical abnormalities; 5. Have immune diseases (such as antiphospholipid antibody syndrome, dryness syndrome, systemic lupus erythematosus, etc.); 6. Have systemic diseases that are poorly controlled (such as thyroid dysfunction, hypertension, diabetes, coronary heart disease, renal insufficiency, etc.); 7. Male factor infertility; 8. Individuals with allergic or contraindicated conditions to exogenous growth hormone.

Design outcomes

Primary

MeasureTime frame
Number of antral follicles;Number of follicles on HCG day;Number of retrieved oocytes;Mitochondrial membrane potential of cumulus granulosa cells;Level of ROS in follicular fluid;Number of fertilizations;Number of superior embryos;Fertilization rate;Superior embryo rate;

Countries

China

Contacts

Public ContactJiang Fangjie

The Second Affiliated Hospital of Kunming Medical University

jiangfangjiess@yeah.net+86 871 6536 8729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026